Teijin Of Japan Buys Licenses To Regenerative Work Of SanBio Of U.S.
This article was originally published in PharmAsia News
Executive Summary
Japan's Teijin has bought a 7 percent stake in SanBio of the United States for $5 million to mark the Japanese company's entry into the regenerative-medicine market